{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/angio-oedema-anaphylaxis/","result":{"data":{"firstChapter":{"id":"f7de7576-f193-57e1-8566-52f77c198d07","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 1577f2fb-5713-49fb-9d7a-b79e5bc4e797 --><h1>Angio-oedema and anaphylaxis: Summary</h1><!-- end field 1577f2fb-5713-49fb-9d7a-b79e5bc4e797 -->","htmlStringContent":"<!-- begin item 4890b8c8-f6a0-4d9b-92fa-ece401187526 --><!-- begin field e4ac15f1-a571-4f0f-ae93-8697721f8b2e --><ul><li>Angio-oedema is swelling of deep dermis, subcutaneous, or submucosal tissue, often affecting the face (lips, tongue, and eyelids), genitalia, hands, or feet. Less commonly, submucosal swelling affects the bowel and airway. The main types are allergic angio-oedema, non-allergic drug reaction (usually caused by angiotensin-converting enzyme [ACE] inhibitor treatment), hereditary angio-oedema (an inherited genetic abnormality), acquired angio-oedema (usually secondary to lymphoma or a connective tissue disorder), and idiopathic angio-oedema.</li><li>Anaphylaxis is a severe, life-threatening, generalized or systemic hypersensitivity reaction characterized by rapidly developing airway and/or breathing and/or circulation problems usually associated with skin and mucosal changes. </li><li>The mechanism for angio-oedema and anaphylaxis is the same, as both histamine and/or bradykinin are involved. However, in anaphylaxis the reaction is more marked, resulting in an increase in vascular permeability and subsequent circulatory collapse.</li><li>Diagnosis of angio-oedema should be based on a thorough clinical history and examination. Investigations may be indicated to identify associated conditions or trigger factors, or to exclude differential diagnoses. </li><li>Resuscitation Council (UK) advises that the Airway, Breathing, Circulation, Disability, Exposure (ABCDE) approach is used to recognize and manage people with anaphylaxis. </li><li>For people with rapidly developing angio-oedema without anaphylaxis, slow intravenous (IV) or intramuscular (IM) chlorphenamine and hydrocortisone should be given, then emergency admission arranged.</li><li>For people with stable angio-oedema without anaphylaxis:<ul><li>The underlying cause should be identified and removed, where possible. </li><li>A non-sedating antihistamine should be offered. For severe symptoms, a short course of an oral corticosteroid should also be offered.</li><li>Referral to an immunologist or dermatologist should be arranged if the cause of angio-oedema is not identifiable or avoidable.</li></ul></li><li>For people with anaphylaxis (which is a medical emergency):<ul><li>An ambulance should be called and help received from colleagues.</li><li>If the person is unresponsive and not breathing normally, cardiopulmonary resuscitation (CPR) should be started immediately.</li><li>IM adrenaline 1:1000 should be given as per age-related guidelines. The response to treatment should be assessed after 5 minutes and IM adrenaline repeated at 5-minute intervals until there has been an adequate response.</li><li>The person should be made comfortable. People with airway and breathing problems may prefer to sit up. Lying flat with or without leg elevation is helpful for people with a low blood pressure. People who are breathing and unconscious should be placed in the recovery position. Pregnant women should lie on their left side to prevent caval compression.</li><li>Where skills and equipment are available, the person should receive high flow oxygen; IV fluid challenge; and monitoring of the pulse, oxygen saturation, blood pressure, and ECG.</li><li>Following initial resuscitation, slow IM or IV chlorphenamine and hydrocortisone should be given. Nebulized salbutamol or ipratropium should be considered if the person is wheezy.</li></ul></li><li>Following emergency treatment for anaphylaxis, the person should be offered:<ul><li>Referral to a specialist allergy service.</li><li>Two adrenaline auto-injectors as an interim measure before their specialist allergy service appointment (and advice on how and when to use them).  </li><li>General information on anaphylaxis.</li></ul></li></ul><!-- end field e4ac15f1-a571-4f0f-ae93-8697721f8b2e --><!-- end item 4890b8c8-f6a0-4d9b-92fa-ece401187526 -->","topic":{"id":"4e83ca20-0eac-5432-adf1-cb9a0716c558","topicId":"41b219ac-b62a-42d3-9d76-7b3897b21bdd","topicName":"Angio-oedema and anaphylaxis","slug":"angio-oedema-anaphylaxis","aliases":[],"chapters":[{"id":"f7de7576-f193-57e1-8566-52f77c198d07","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"137d41e2-195c-5b6c-a42b-a2e7774ab4c5","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"2d19b26a-ca5e-5feb-8be8-12f596f24eed","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"76defb8d-d620-56bc-bf42-cc72dd02704f","slug":"changes","fullItemName":"Changes"},{"id":"0124664c-1848-504a-b629-b001f3d627e7","slug":"update","fullItemName":"Update"}]},{"id":"fd3fe5d3-198d-5e2e-afaa-1de509ee14b0","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"8c36d3c5-8fc2-58ba-91d9-2d00dbb17605","slug":"goals","fullItemName":"Goals"},{"id":"dbfbfeb0-8ad4-5a3d-8458-06af672eab12","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bbc732dc-6fbc-5902-a5bf-890776f1df44","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"49ccfcd1-6054-5eac-b6a2-c85eb605ecfd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4c97855a-e489-54e6-8f4b-28dbc050951e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"71eafab9-7c66-5e57-aa08-197ad09eb9e7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2c158e9f-bfe1-56ea-a1fe-97e4da83b82d","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"ed1b7bb1-0232-5ceb-991c-c936ac2a3086","slug":"definition","fullItemName":"Definition"},{"id":"ac67665b-2b88-5df8-9a70-cc35f96825ae","slug":"causes-trigger-factors","fullItemName":"Causes/trigger factors"},{"id":"a4358430-db1f-55c2-9d68-6ce8076813ba","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7ebee135-258e-58ce-a91e-947b8a2f9563","slug":"complications","fullItemName":"Complications"},{"id":"7c2a6ca1-0f6a-5a40-bc06-dbbbf95c57c1","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4b20303c-5905-594a-a8c6-4f85e46cf3f9","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"005b06b8-18c4-569f-b1b3-3c6d1218ddf7","slug":"diagnosis-of-angio-oedema","fullItemName":"Diagnosis of angio-oedema"},{"id":"682e56cf-4c4d-5736-8db7-4cd4bfcab6e2","slug":"assessing-the-cause-of-angio-oedema","fullItemName":"Assessing the cause of angio-oedema"},{"id":"bf860a63-b9a4-5c14-bf1b-46423d3df7ad","slug":"diagnosis-of-anaphylaxis","fullItemName":"Diagnosis of anaphylaxis"},{"id":"fab5c932-e15e-5303-99e9-48f7d2e415b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1c5f38ef-17d4-569d-ad54-b819fd953d6c","slug":"management","fullItemName":"Management","subChapters":[{"id":"654a5e70-49b7-58b4-b976-7e94c44b3074","slug":"angio-oedema-without-anaphylaxis","fullItemName":"Scenario: Angio-oedema without anaphylaxis"},{"id":"5759117d-4bde-53b6-b78d-7885ccbf431e","slug":"anaphylaxis-with-or-without-angio-oedema","fullItemName":"Scenario: Anaphylaxis with or without angio-oedema"}]},{"id":"6f94e28f-193d-587a-a11a-0a05a1be037f","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"b59ab8fd-de1f-555e-946a-c3a53b918da4","slug":"emergency-drug-doses","fullItemName":"Emergency drug doses"},{"id":"69e007b8-2046-5946-a7b5-de8f1bb9de9f","slug":"non-sedating-antihistamines-no-airway-involvement","fullItemName":"Non-sedating antihistamines (no airway involvement)"},{"id":"dac089ca-3b63-536d-9737-82806f78b88e","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"}]},{"id":"7ead2f48-36a4-5547-8570-4d4ab5898a73","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"a7653e34-460d-5737-b0c3-264ecc26dc68","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"a713ee82-3188-50ea-a2bc-a562abd97621","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7421fd02-2e34-5526-bd39-905aa772f800","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d24df800-eddc-5bf3-bea0-d556b5e01aed","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"af27ed5c-0853-5d16-91a4-5e5878ee9209","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f7640a76-8bc4-569e-8b82-717e6bd5f041","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b4778aa1-f37d-574f-8514-47ac86bf2c2e","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"4e83ca20-0eac-5432-adf1-cb9a0716c558","topicId":"41b219ac-b62a-42d3-9d76-7b3897b21bdd","topicName":"Angio-oedema and anaphylaxis","slug":"angio-oedema-anaphylaxis","aliases":[],"topicSummary":"Angio-oedema is swelling of deep dermis, subcutaneous, or submucosal tissue, often affecting the face, genitalia, hands, or feet.","lastRevised":"Last revised in November 2018","nextPlannedReviewBy":"2022-11-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2022-11","nextPlannedReviewByDisplay":"November 2022","specialities":[{"id":"861c4fe3-02c7-51e0-8f03-a114c375ba4d","name":"Allergies","slug":"allergies"},{"id":"2454765b-1b2d-53fc-b288-17b66486f41a","name":"Preventative medicine","slug":"preventative-medicine"},{"id":"50071c38-ab10-5ab8-ac70-6bd19a96c24e","name":"Skin and nail","slug":"skin-nail"}],"chapters":[{"id":"f7de7576-f193-57e1-8566-52f77c198d07","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"137d41e2-195c-5b6c-a42b-a2e7774ab4c5","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"2d19b26a-ca5e-5feb-8be8-12f596f24eed","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"76defb8d-d620-56bc-bf42-cc72dd02704f","slug":"changes","fullItemName":"Changes"},{"id":"0124664c-1848-504a-b629-b001f3d627e7","slug":"update","fullItemName":"Update"}]},{"id":"fd3fe5d3-198d-5e2e-afaa-1de509ee14b0","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"8c36d3c5-8fc2-58ba-91d9-2d00dbb17605","slug":"goals","fullItemName":"Goals"},{"id":"dbfbfeb0-8ad4-5a3d-8458-06af672eab12","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bbc732dc-6fbc-5902-a5bf-890776f1df44","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"49ccfcd1-6054-5eac-b6a2-c85eb605ecfd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4c97855a-e489-54e6-8f4b-28dbc050951e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"71eafab9-7c66-5e57-aa08-197ad09eb9e7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2c158e9f-bfe1-56ea-a1fe-97e4da83b82d","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"ed1b7bb1-0232-5ceb-991c-c936ac2a3086","slug":"definition","fullItemName":"Definition"},{"id":"ac67665b-2b88-5df8-9a70-cc35f96825ae","slug":"causes-trigger-factors","fullItemName":"Causes/trigger factors"},{"id":"a4358430-db1f-55c2-9d68-6ce8076813ba","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7ebee135-258e-58ce-a91e-947b8a2f9563","slug":"complications","fullItemName":"Complications"},{"id":"7c2a6ca1-0f6a-5a40-bc06-dbbbf95c57c1","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4b20303c-5905-594a-a8c6-4f85e46cf3f9","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"005b06b8-18c4-569f-b1b3-3c6d1218ddf7","slug":"diagnosis-of-angio-oedema","fullItemName":"Diagnosis of angio-oedema"},{"id":"682e56cf-4c4d-5736-8db7-4cd4bfcab6e2","slug":"assessing-the-cause-of-angio-oedema","fullItemName":"Assessing the cause of angio-oedema"},{"id":"bf860a63-b9a4-5c14-bf1b-46423d3df7ad","slug":"diagnosis-of-anaphylaxis","fullItemName":"Diagnosis of anaphylaxis"},{"id":"fab5c932-e15e-5303-99e9-48f7d2e415b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1c5f38ef-17d4-569d-ad54-b819fd953d6c","slug":"management","fullItemName":"Management","subChapters":[{"id":"654a5e70-49b7-58b4-b976-7e94c44b3074","slug":"angio-oedema-without-anaphylaxis","fullItemName":"Scenario: Angio-oedema without anaphylaxis"},{"id":"5759117d-4bde-53b6-b78d-7885ccbf431e","slug":"anaphylaxis-with-or-without-angio-oedema","fullItemName":"Scenario: Anaphylaxis with or without angio-oedema"}]},{"id":"6f94e28f-193d-587a-a11a-0a05a1be037f","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"b59ab8fd-de1f-555e-946a-c3a53b918da4","slug":"emergency-drug-doses","fullItemName":"Emergency drug doses"},{"id":"69e007b8-2046-5946-a7b5-de8f1bb9de9f","slug":"non-sedating-antihistamines-no-airway-involvement","fullItemName":"Non-sedating antihistamines (no airway involvement)"},{"id":"dac089ca-3b63-536d-9737-82806f78b88e","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"}]},{"id":"7ead2f48-36a4-5547-8570-4d4ab5898a73","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"a7653e34-460d-5737-b0c3-264ecc26dc68","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"a713ee82-3188-50ea-a2bc-a562abd97621","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7421fd02-2e34-5526-bd39-905aa772f800","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d24df800-eddc-5bf3-bea0-d556b5e01aed","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"af27ed5c-0853-5d16-91a4-5e5878ee9209","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f7640a76-8bc4-569e-8b82-717e6bd5f041","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b4778aa1-f37d-574f-8514-47ac86bf2c2e","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"4e83ca20-0eac-5432-adf1-cb9a0716c558"}},"staticQueryHashes":["3666801979"]}